reports
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
- Life Sciences & Chemicals Team
ODDO : Defensive growth sectors
We are publishing our first slideshow on our Life Sciences & Chemicals macropole. Our expertise integrates many sub-sectors which have been schematically separated into pharma, medtech, biotech, healthcare services and chemicals. The objective here is to review on a quarterly basis the key points of our respective sectors, by publishing both the financial and market metrics as well as the stocks that we recommend. - >Pharma’s defensive role validated thanks to a reassuring...
SOON SONOVA HOLDING AG
DSM KONINKLIJKE DSM N.V.
FME FRESENIUS MEDICAL CARE AG & CO. KGAA
1COV COVESTRO AG
BOI BOIRON SA
IPN IPSEN SA
WCH WACKER CHEMIE AG
ROG ROCHE HOLDING LTD
MDG1 MEDIGENE AG
NOVN NOVARTIS AG
QIA QIAGEN NV
PA8 PAION AG
SBS STRATEC SE
TNG TRANSGENE SA
BIO BB BIOTECH AG
KORI KORIAN SA
AFX CARL ZEISS MEDITEC AG
SRT3 SARTORIUS AG PREF
DEMANT DEMANT A/S
RHK RHON-KLINIKUM AG
LXS LANXESS AG
GXI GERRESHEIMER AG
ABVX ABIVAX SA
BLC BASTIDE LE CONFORT MEDICAL SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
LNA LNA SANTE SA
GBT GUERBET SA
ALCLS CELLECTIS SA
MRK MERCK KGAA
NOVO B NOVO NORDISK A/S CLASS B
ALCAR CARMAT SA
SDF K+S AG
GRF GRIFOLS S.A. CLASS A
GN GN STORE NORD A/S
BAS BASF SE
SAN SANOFI
FRE FRESENIUS SE & CO. KGAA
SOLB SOLVAY SA
BAYN BAYER AG
UCB UCB S.A.
ORP ORPEA SA
SY1 SYMRISE AG
AMP AMPLIFON S.P.A.
FAE FAES FARMA S.A.
KWS KWS SAAT SE & CO KGAA
SZU SUEDZUCKER AG
GNFT GENFIT SA
EVK EVONIK INDUSTRIES AG
DIM SARTORIUS STEDIM BIOTECH SA
REC RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
ADOC ADOCIA SA
BNR BRENNTAG SE
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
ALM ALMIRALL SA
GRF.P GRIFOLS S.A. PREF CLASS B
COPN COSMO PHARMACEUTICALS NV
AZN ASTRAZENECA PLC
ALVAL VALBIOTIS SA
VIFN VIFOR PHARMA AG
BIM BIOMERIEUX SA
ALTHX THERANEXUS SA
2HRA H&R GMBH & CO KGAA
DMP DERMAPHARM HOLDING SE
SHL SIEMENS HEALTHINEERS AG
MOR MORPHOSYS AG
MEDCL MEDINCELL SA
AKZA AKZO NOBEL N.V.
MRNA MODERNA INC.
BNTX BIONTECH SE
ZEL PHARMA MAR SA
FPE3 FUCHS PETROLUB SE
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
GSK GSK PLC
BAI BENEVOLENTAI
EQS-News: PAION AG implements resolved capital reduction
EQS-News: PAION AG / Key word(s): Miscellaneous PAION AG implements resolved capital reduction 31.03.2023 / 19:15 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG implements resolved capital reduction Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordinary General Meeting of PAION AG on...
EQS-News: PAION AG setzt beschlossene Kapitalherabsetzung um
EQS-News: PAION AG / Schlagwort(e): Sonstiges PAION AG setzt beschlossene Kapitalherabsetzung um 31.03.2023 / 19:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG setzt beschlossene Kapitalherabsetzung um Aachen, 31. März 2023 – Die PAION AG (ISIN DE000A0B65S3; Frankfurter Wertpapierbörse, Prime Standard: PA8), ein Specialty-Pharma-Unternehmen mit innovativen Wirkstoffen zur Anwendung bei ambulanter und im Krankenhaus durchgeführter Sedierung, Anästhesie sowie in der Intensivmedizin gibt bekannt, dass die Beschlüsse...
EQS-News: PAION AG berichtet über Geschäftsjahr 2022
EQS-News: PAION AG / Schlagwort(e): Jahresergebnis PAION AG berichtet über Geschäftsjahr 2022 30.03.2023 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG berichtet über Geschäftsjahr 2022 Kombinierte Umsatzerlöse in Höhe von EUR 33,2 Mio. Liquide Mittel in Höhe von EUR 10,6 Mio. zum 31. Dezember 2022 Positives EBITDA in Höhe von EUR 1,5 Mio. Kapitalherabsetzung im ersten Quartal 2023 durchgeführt Initiativen zum Ausbau des kommerziellen Vertriebs fortgeführt, darunter die erfolgreiche Erweiterung der Partne...
EQS-News: PAION AG reports on fiscal year 2022
EQS-News: PAION AG / Key word(s): Annual Results PAION AG reports on fiscal year 2022 30.03.2023 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG reports on fiscal year 2022 Combined revenues of EUR 33.2 million Cash and cash equivalents of EUR 10.6 million as of 31 December 2022 Positive EBITDA of EUR 1.5 million Capital reduction carried out in the first quarter of 2023 Initiatives to expand commercial distribution continued, including the successful expansion of partner networks through licensing and cooperation ag...
EQS-News: PAION VERANSTALTET GESPONSERTES ANGIOTENSIN-II-SYMPOSIUM AUF...
EQS-News: PAION AG / Schlagwort(e): Konferenz PAION VERANSTALTET GESPONSERTES ANGIOTENSIN-II-SYMPOSIUM AUF DEM ISICEM IN BRÜSSEL 16.03.2023 / 10:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION VERANSTALTET GESPONSERTES ANGIOTENSIN-II-SYMPOSIUM AUF DEM ISICEM IN BRÜSSEL Gesponsertes Symposium & Posterpräsentation über Angiotensin II auf dem 42. ISICEM Kongress, 21. - 24. März 2023 in Brüssel PAION präsentiert neue Daten aus einer Post-hoc-Analyse der ATHOS-3-Studie mit Angiotensin II Aachen, 16. März 2023 – Die PAION A...
EQS-News: PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISI...
EQS-News: PAION AG / Key word(s): Conference PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS 16.03.2023 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfur...
- Oliver Metzger
SN. SMITH & NEPHEW PLC
OSE OSE IMMUNOTHERAPEUTICS SA
PBB DEUTSCHE PFANDBRIEFBANK AG
QIA QIAGEN NV
PA8 PAION AG
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
ICAD ICADE SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
DMP DERMAPHARM HOLDING SE
MEDCL MEDINCELL SA
AEIN ALLGEIER HOLDING AG
DSC1 DUTCH STAR C SHAR
MAJ MAJOREL GRP SA(LUXEMBOURG)
SYAB SYNLAB AG
EFIC1 EUROPEAN FINTECH IPO CO 1 BV
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
BAI BENEVOLENTAI
- Oliver Metzger
SN. SMITH & NEPHEW PLC
OSE OSE IMMUNOTHERAPEUTICS SA
PBB DEUTSCHE PFANDBRIEFBANK AG
QIA QIAGEN NV
PA8 PAION AG
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
ICAD ICADE SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
DMP DERMAPHARM HOLDING SE
MEDCL MEDINCELL SA
AEIN ALLGEIER HOLDING AG
DSC1 DUTCH STAR C SHAR
MAJ MAJOREL GRP SA(LUXEMBOURG)
SYAB SYNLAB AG
EFIC1 EUROPEAN FINTECH IPO CO 1 BV
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
BAI BENEVOLENTAI
- Antonio Rodriguez Vicens
ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/03/2023
La notion d’Energy Security, apparue avec le conflit entre la Russie et l’Ukraine, vient renforcer celle de supercycle, plusieurs fois évoquée. La reprise des investissements n’est plus hypothétique et devrait se poursuivre au moins sur les 5 prochaines années, non seulement dans le GNL mais aussi en offshore. Nous relevons nos attentes de Capex 2022/26 de 10%, qui devraient dépasser le précédent point haut de 2014 à cet horizon. Dans ce contexte, nous privilégions Technip Energies, T...
SN. SMITH & NEPHEW PLC
FRA FRAPORT AG
WCH WACKER CHEMIE AG
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
PA8 PAION AG
HNR1 HANNOVER RUECK SE
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
MEDCL MEDINCELL SA
PHNX PHOENIX GROUP HOLDINGS PLC
SYAB SYNLAB AG
AZE AZELIS GROUP NV
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
BAI BENEVOLENTAI
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
- Antonio Rodriguez Vicens
ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/14/2023
The idea of energy security, which emerged with the conflict between Russia and Ukraine, has strengthened that of the supercycle, as previously highlighted. The upturn in investment is no longer hypothetical and is set to continue over the next five years at least, not only in LNG but also offshore. We have raised our 2022-2026 capex expectations by 10%, with the previous high of 2014 set to be topped by then. Against this backdrop, we prefer Technip Energies, Technip FMC and Valloure...
SN. SMITH & NEPHEW PLC
FRA FRAPORT AG
WCH WACKER CHEMIE AG
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
PA8 PAION AG
HNR1 HANNOVER RUECK SE
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
MEDCL MEDINCELL SA
PHNX PHOENIX GROUP HOLDINGS PLC
SYAB SYNLAB AG
AZE AZELIS GROUP NV
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
BAI BENEVOLENTAI
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
- Team Pharma
ODDO : French and European biotechs broadly protected from SVB
>A marginal impact from SVB’ bankruptcy on the French biotechs - The bankruptcy of the American bank SVB announced last Friday has weighed on the technology and healthcare sectors. Indeed, SVB had a very strong focus of strong-growth technology stocks. Bearing in mind that we are talking about sectors that require a high level of financing it is legitimate to question the risk to the biotechnology sector in Europe. Moreover, we have contacted all of the groups in our...
SN. SMITH & NEPHEW PLC
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
PA8 PAION AG
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
MEDCL MEDINCELL SA
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
BAI BENEVOLENTAI
- Team Pharma
ODDO : Biotechs françaises et européennes globalement protégées de SVB
>Un impact marginal de la faillite de SVB sur les biotechs françaises - La faillite de la banque américaine SVB annoncée vendredi dernier a pesé sur le secteur des Technologies et de la Santé. En effet, SVB avait un prisme très fort sur les valeurs de technologies à forte croissance. Sachant que nous parlons de secteurs où le besoin en financement est important, il est juste de se poser la question du risque sur le secteur des biotechnologies en Europe. Aussi, nous av...
SN. SMITH & NEPHEW PLC
OSE OSE IMMUNOTHERAPEUTICS SA
QIA QIAGEN NV
PA8 PAION AG
TNG TRANSGENE SA
AFX CARL ZEISS MEDITEC AG
A1XAEB QUANTUM GENOMICS
RHK RHON-KLINIKUM AG
ABVX ABIVAX SA
FAGR FAGRON SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
MKEA MAUNA KEA TECHNOLOGIES SA CLASS O
ALCLS CELLECTIS SA
ALCAR CARMAT SA
FIE FIELMANN AG
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
DIM SARTORIUS STEDIM BIOTECH SA
ADOC ADOCIA SA
COLO B COLOPLAST A/S CLASS B
POXEL POXEL SA
COPN COSMO PHARMACEUTICALS NV
ALVAL VALBIOTIS SA
ALTHX THERANEXUS SA
MEDCL MEDINCELL SA
SYAB SYNLAB AG
AELIS AELIS FARMA SA
EAPI EUROAPI
STMN STRAUMANN HOLDING AG
BAI BENEVOLENTAI
EQS-News: PAION AG: Außerordentliche Hauptversammlung stimmt Kapitalhe...
EQS-News: PAION AG / Schlagwort(e): Hauptversammlung PAION AG: Außerordentliche Hauptversammlung stimmt Kapitalherabsetzungen zu und schafft Spielraum für weitere Unternehmensfinanzierung 25.01.2023 / 17:35 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG: Außerordentliche Hauptversammlung stimmt Kapitalherabsetzungen zu und schafft Spielraum für weitere Unternehmensfinanzierung Aachen, 25. Januar 2023 – Die PAION AG (ISIN DE000A0B65S3; Frankfurter Wertpapierbörse, Prime Standard: PA8), ein Specialty-Pharma-Unternehmen mit i...
EQS-News: PAION AG: Extraordinary General Meeting approves capital red...
EQS-News: PAION AG / Key word(s): AGM/EGM PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing 25.01.2023 / 17:35 CET/CEST The issuer is solely responsible for the content of this announcement. PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing Aachen (Germany), 25 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and ...
EQS-News: PAION GIBT EINREICHUNG DES REMIMAZOLAM-MARKTZULASSUNG...
EQS-News: PAION AG / Schlagwort(e): Zulassungsantrag PAION GIBT EINREICHUNG DES REMIMAZOLAM-MARKTZULASSUNGSANTRAGS DURCH SEINEN LIZENZNEHMER CRISTÁLIA IN BRASILIEN BEKANNT 19.01.2023 / 10:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION GIBT EINREICHUNG DES REMIMAZOLAM-MARKTZULASSUNGSANTRAGS DURCH SEINEN LIZENZNEHMER CRISTÁLIA IN BRASILIEN BEKANNT Aachen, 19. Januar 2023 – Die PAION AG (ISIN DE000A0B65S3; Frankfurter Wertpapierbörse, Prime Standard: PA8), ein Specialty-Pharma-Unternehmen mit innovativen Wirkstoffen zu...
EQS-News: PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FO...
EQS-News: PAION AG / Key word(s): Regulatory Admission PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL 19.01.2023 / 10:30 CET/CEST The issuer is solely responsible for the content of this announcement. PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL Aachen (Germany), 19 January 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospit...
Paion AG: 1 director
A director at Paion AG bought 50,000 shares at 0.482EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
EQS-News: PAION AG gibt Stellungnahme zur geplanten Kapitalmaßnahme ab
EQS-News: PAION AG / Schlagwort(e): Kapitalmaßnahme PAION AG gibt Stellungnahme zur geplanten Kapitalmaßnahme ab 16.12.2022 / 10:19 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PAION AG gibt Stellungnahme zur geplanten Kapitalmaßnahme ab Aachen, 16. Dezember 2022 – Die PAION AG (ISIN DE000A0B65S3; Frankfurter Wertpapierbörse, Prime Standard: PA8), ein Specialty-Pharma-Unternehmen mit innovativen Wirkstoffen zur Anwendung bei ambulanter und im Krankenhaus durchgeführter Sedierung, Anästhesie sowie in der Intensivmedizin, hat am Mit...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.